Marker for predicting tumor reactivity of lymphocytes, and use thereof

Abstract

The present invention relates to a marker for predicting a tumor reactivity of lymphocytes, a composition for predicting a tumor reactivity, and a method for predicting a tumor reactivity. Using the genetic marker according to the present invention, a predictive model that can predict the tumor reactivity of cultured lymphocytes may be constructed, and it is possible to more accurately select tumor-specific lymphocytes to produce an effective immunotherapeutic agent, by predicting the reactivity of the lymphocytes through the present invention. In addition, by using the above genetic markers, it is possible to more conveniently and non-invasively separate lymphocytes from body tissues, blood, or body fluids, deviating from the conventional invasive methods, and to select only lymphocytes with tumor-specific activity, for immunotherapy. It is expected to widely use with various application.

1 . A composition for predicting a reactivity of a lymphocyte against a tumor, comprising an agent capable of measuring a mRNA level or an agent capable of measuring a protein level for ITGA6 gene (Genbank accession number: NM_000210.4, NM 001079818.3, NM 001316306.2, NM 001365529.2 or NM_00 1365530.2). 
     
     
         2 . The composition of  claim 1 , wherein the composition further comprises an agent capable of measuring a mRNA level or an agent capable of measuring a protein level for at least one gene selected from the group consisting of
 ATP6V0A1(Genbank accession number: NM 001130020.3 NM 001130021.3 NM 001378522.1NM_001378523.1 or NM_001378530.1),   ARRDC3(Genbank accession number: NM 001329670.2, NM 001329671.2, NM_001329672.2 and NM_020801.4),   CD23(Genbank accession number: NM 001207019.2, NM 001220500.2 or NM 002002.4),   CD200(Genbank accession number: NM_001004196.3, NM 001318826.1, NM 001318828.1, NM 001318830.1 or NM_001365851.2),   CD300C(Genbank accession number: NM 006678.5), CYSLTR1(Genbank accession number: NM_001282186.1 NM_001282187.2 NM_001282188.2 or NM 006639.4),   ITGB1(Genbank accession number: NM_002211.4, NM_033668.2 or NM_133376.2),   MBOAT2(Genbank accession number: NM 001321265.2, NM 001321266.2, NM_001321267.2 or NM_138799.4),   Met(Genbank accession number: NM 000245.4, NM 001127500.3, NM 001324401.2 or NM_001324402.2),   MYO9A(Genbank accession number: NM 006901.4),   PTPN13(Genbank accession number: NM_006264.3, NM_080683.3, NM_080684.3 or NM_080685.2),   S100P(Genbank accession number: NM 005980.3),   SECTM 1 (Genbank accession number: NM_003004.3),   TCN2(Genbank accession number: NM 000355.4 or NM 001184726.1),   TSPAN2(Genbank accession number: NM_001308315.1, NM_001308316.1 or NM_005725.6) and   VSIG1(Genbank accession number: NM 001170553.1 or NM_182607.5).   
     
     
         3 . The composition of  claim 1 , wherein the lymphocyte is isolated from tumor tissue, blood or body fluid of a subject having the tumor. 
     
     
         4 . The composition of  claim 1 , wherein the agent capable of measuring the mRNA level is a sense primer, an antisense primer or probe, which are capable of complementarily binding to the mRNA of the gene. 
     
     
         5 . The composition of  claim 1 , wherein the agent capable of measuring the protein level is an antibody that specifically binds to the protein encoded by the gene. 
     
     
         6 . The composition of  claim 1 , wherein the tumor is breast cancer. 
     
     
         7 - 12 . (canceled) 
     
     
         13 . A method for predicting a reactivity of a lymphocyte against a tumor, the method comprising measuring a mRNA level or a protein level for ITGA6 gene (Genbank accession number: NM 000210.4, NM_001079818.3, NM_001316306.2, NM_001365529.2 or NM 001365530.2) 
     
     
         14 . The method of  claim 13 , wherein the method further comprises measuring a mRNA level or a protein level for at least one gene selected from the group consisting of
 ARRDC3(Genbank accession number: NM 001329670.2, NM 001329671.2, NM_001329672.2 and NM_020801.4),
 CD23(Genbank accession number: NM 001207019.2, NM 001220500.2 or NM 002002.4), 
 CD200(Genbank accession number: NM_001004196.3, NM 001318826.1, NM 001318828.1, NM_001318830.1 or NM_001365851.2), 
 CD300C(Genbank accession number: NM 006678.5), 
 CYSLTR1(Genbank accession number: NM_001282186.1 NM_001282187.2 NM_001282188.2 or NM 006639.4), 
 ITGB1(Genbank accession number: NM_002211.4, NM_033668.2 or NM_133376.2), 
 MBOAT2(Genbank accession number: NM 001321265.2, NM 001321266.2, NM 001321267.2 or NM 138799.4), 
 Met(Genbank accession number: NM 000245.4, NM 001127500.3, NM 001324401.2 or NM_001324402.2), 
 MYO9A(Genbank accession number: NM 006901.4), 
 PTPN13(Genbank accession number: NM_006264.3, NM_080683.3, NM_080684.3 or NM 080685.2), 
 S100P(Genbank accession number: NM 005980.3), 
 SECTM 1 (Genbank accession number: NM_003004.3), 
 TCN2(Genbank accession number: NM 000355.4 or NM 001184726.1), 
 TSPAN2(Genbank accession number: NM_001308315.1, NM_001308316.1 or NM_005725.6) and 
 VSIG1(Genbank accession number: NM 001170553.1 or NM_182607.5). 
   
     
     
         15 . The method of  claim 13 , wherein the tumor is breast cancer. 
     
     
         16 . The method of  claim 13 , wherein the lymphocyte is isolated from tumor tissue, blood or body fluid of a subject having the tumor. 
     
     
         17 . The method of  claim 16 , wherein the mRNA or the protein to be measured is a mRNA or a protein of the lymphocyte.